This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wautier, J.-L. Articles by Schmidt, A. M. Search for Related Content PubMed PubMed Citation Articles by Wautier, J.-L. Articles by Schmidt, A. M. Related Collections Endothelium/vascular type/nitric oxide Mechanism of atherosclerosis/growth factors

(Circulation Research. 2004;95:233.)
© 2004 American Heart Association, Inc.

Reviews

Protein Glycation

A Firm Link to Endothelial Cell Dysfunction

Jean-Luc Wautier, Ann Marie Schmidt

From the University Lariboisiere-Saint Louis and Institut National de la Transfusion Sanguine (J.-L.W.), Paris, France; and Columbia University (A.M.S.), College of Physicians & Surgeons, New York, NY.

Correspondence to Jean-Luc Wautier, MD, PhD, University Lariboisiere-Saint Louis, Paris 7, INTS, Vascular and cellular biology Laboratory, 6 rue Alexandre Cabanel, 75739 Paris cedex 15, France. E-mail jlwautier{at}ints.fr

This Review is part of a thematic series on Cardiovascular Role of Sugar Modifications, which includes the following articles:

Glycation, Inflammation, and RAGE: A Scaffold for the Macrovascular Complications of Diabetes and Beyond

Protein Glycation: A Firm Link to Endothelial Cell Dysfunction
David A. Kass Editor

	Abstract

Top Abstract Introduction Maillard Reaction Cellular and Extracellular AGE... Methylglyoxal Is Efficiently... Endothelial Cell Dysfunction Retinopathy Nephropathy Endothelial Cell Activation Endothelial Cell Growth,... Conclusion References

 
The advanced glycation end products (AGEs) are a heterogeneous class of molecules, including the following main subgroups: bis(lysyl)imidazolium cross-links, hydroimidazolones, 3-deoxyglucosone derivatives, and monolysyl adducts. AGEs are increased in diabetes, renal failure, and aging. Microvascular lesions correlate with the accumulation of AGEs, as demonstrated in diabetic retinopathy or renal glomerulosclerosis. On endothelial cells, ligation of receptor for AGE (RAGE) by AGEs induces the expression of cell adhesion molecules, tissue factor, cytokines such as interleukin-6, and monocyte chemoattractant protein-1. A chief means by which AGEs via RAGE exert their effects is by generation of reactive oxygen species, at least in part via stimulation of NADPH oxidase. Diabetes-associated vascular dysfunction in vivo can be prevented by blockade of RAGE. Thus, agents that limit AGE formation, increase the catabolism of these species, or antagonize their binding to RAGE may provide new targets for vascular protection in diabetes.

Key Words: glycated proteins • (carboxymethyl)lysine • 3-deoxyglucosone • endothelial cells • vascular permeability • oxidant stress

	Introduction

Top Abstract Introduction Maillard Reaction Cellular and Extracellular AGE... Methylglyoxal Is Efficiently... Endothelial Cell Dysfunction Retinopathy Nephropathy Endothelial Cell Activation Endothelial Cell Growth,... Conclusion References

 
Nonenzymatic protein glycation (glucosylation or glycosylation) by glucose is a complex cascade of reactions yielding a heterogeneous class of compounds, collectively termed advanced glycation end products (AGEs). Nonenzymatic glycation of proteins described by Louis-Camille Maillard¹ have been implicated in the pathogenesis of diabetes, renal failure, and aging.² In vitro–prepared AGE modifications of proteins have been shown to be toxic, immunogenic, and capable of triggering cellular injury.

	Maillard Reaction

Top Abstract Introduction Maillard Reaction Cellular and Extracellular AGE... Methylglyoxal Is Efficiently... Endothelial Cell Dysfunction Retinopathy Nephropathy Endothelial Cell Activation Endothelial Cell Growth,... Conclusion References

 
The Maillard reaction begins with the reaction of the carbonyl (aldehyde or ketone) of the reducing sugar to form a reversible Schiff base with the amino group of the biomolecule. The Schiff base can undergo an intramolecular rearrangement to form the Amadori products;³ this can undergo a series of further rearrangements, dehydration, and condensation to form irreversible end products, which may be fluorescent and yellow–brown in color; some can form stable intermolecular and intramolecular cross-links (Figure 1).⁴ In vivo, the amount of AGEs on a protein has been found to be dependent on the inherent reactivity of specific amino groups, as determined by their microenvironment, the glucose concentration, and the half-life of the protein. Realization of the importance of Maillard-like reactions in vivo began in the mid-1970s with the study of hemoglobin A1c (HbA1c),⁵ a naturally occurring minor human hemoglobin that is elevated in diabetic patients. HbA1c is known to be a posttranslational adduct of glucose with the N-terminal valine amino group of the ß chain of hemoglobin, in which the glucose was thought to be attached via a nonenzymatically formed Schiff base structure. In fact, the carbohydrate in HbA1c is attached as a 1-deoxy-1-fructosyl residue to the N-terminal valine nitrogen derived from an initially formed Schiff base via an Amadori rearrangement. HbA1c is used for assessing extended metabolic control in diabetic patients and provides an average integrated blood glucose concentration for approximately a 28-day period.

View larger version (20K): [in this window] [in a new window]   Figure 1. Maillard reaction.

Glycation adducts are formed by the reaction of proteins with glucose-reactive -oxoaldehydes such as glyoxal, methylglyoxal, and 3-deoxyglucosone, and other saccharide derivatives.⁶ The initial Schiff base adducts formed from glucose and lysine and N-terminal amino-acid residues rearrange to form fructosamine. Fructosamine degradation and the direct reaction of -oxoaldehydes with protein form many AGEs. Oxidative reactions may be increased by oxidative stress arising from mitochondrial dysfunction and activation of NADPH oxidase.^7–8 Some AGEs are cross-linked, for example, the bis(lysyl)imidazolium salts may denature proteins and confer resistance to proteolysis. When AGEs are formed at critical sites in enzymes or proteins, they may be associated with enzyme inactivation.⁹

Cross-linked AGEs, GOLD [glyoxal-derived lysine dimer, 1,3-di(N-lysino imidazolium salt], MOLD [methylglyoxal-derived lysine dimer, 1,3-di(N-lysino)-4-(methyl-imidazolium salt], DOLD [3-deoxyglucosone-derived lysine dimer, 1,3-di(N-lysino)-4 (2,3,4-trihydroxybutyl)imidazolium salt], and pentosidine may alter protein structure and function (Table).^3–10

View this table: [in this window] [in a new window]   Table 1. AGE Products

	Cellular and Extracellular AGE-Modified Proteins

Top Abstract Introduction Maillard Reaction Cellular and Extracellular AGE... Methylglyoxal Is Efficiently... Endothelial Cell Dysfunction Retinopathy Nephropathy Endothelial Cell Activation Endothelial Cell Growth,... Conclusion References

 
The concentrations of AGEs in protein of human blood cells and plasma in vivo and human kidney mesangial cells can be determined by liquid chromatography mass spectrometry.¹⁰ The concentration of AGEs is higher in cellular protein than in plasma protein. N-carboxymethyl-lysine plasma protein is 21 µmol/mol of lysine, whereas cellular N-carboxymethyl-lysine concentration reaches 68 to 233 mmol/mol of lysine. MOLD was found in plasma (0.8 µmol/mol of lysine) and in red blood cells (5.3 µmol/mol of lysine).

AGE content may increase rapidly; a 13.8-fold increase in AGE levels within 1 week has been demonstrated in endothelial cells. Hyperglycemia-induced increases in endothelial cell macromolecular endocytosis can be prevented by inhibition of methylglyoxal-derived intracellular AGEs.⁶ AGEs arise from both metal-catalyzed auto-oxidation of glucose with the dicarbonyl glyoxal and arabinose as intermediates, and from decomposition of Amadori products to the dicarbonyl 3-deoxyglucosone. The dicarbonyl methylglyoxal produced by nonenzymatic fragmentation of triose phosphate also forms AGE in vitro.

	Methylglyoxal Is Efficiently Metabolized by the Glyoxalase System

Top Abstract Introduction Maillard Reaction Cellular and Extracellular AGE... Methylglyoxal Is Efficiently... Endothelial Cell Dysfunction Retinopathy Nephropathy Endothelial Cell Activation Endothelial Cell Growth,... Conclusion References

 
Incubation of GM7373 endothelial cells that stably express human glyoxalase-I in high glucose concentration (30 µmol/L) did not result in increased AGE formation whereas the AGE content in the nontransfected cells was increased 13.6-fold, demonstrating that enzymatic defense¹¹ against glycation may represent an approach to limit the deleterious consequences of AGEs. Oxidative stress is inextricably linked to glycation because the depletion of GSH and NADPH also decreases the in situ activities of glyoxalase-I and NADPH-dependent aldehyde reductases.¹²

	Endothelial Cell Dysfunction

Top Abstract Introduction Maillard Reaction Cellular and Extracellular AGE... Methylglyoxal Is Efficiently... Endothelial Cell Dysfunction Retinopathy Nephropathy Endothelial Cell Activation Endothelial Cell Growth,... Conclusion References

 
Endothelial cell dysfunction, a broad term that implies reduced production of nitric oxide (NO) and an imbalance in the relative contribution of endothelium relaxing and contracting factors and oxidants, is emerging as a key component in the pathophysiology of diverse cardiovascular abnormalities associated with atherosclerosis, hypertension, diabetes, renal failure, and aging.^13,14 In addition to its vasodilatory effect, NO also protects against vascular injury, inflammation, and leukocyte adhesion. When endothelial cells undergo inflammatory activation, the increased expression of selectins, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 may promote the adherence of monocytes.^15–17 Adherent monocytes transmigrate into the arterial wall, passing between the endothelial cells. Endothelial cells, rather than providing protection against thrombosis, then become prothrombotic and may produce tissue factor (Figure 2).¹⁸

View larger version (38K): [in this window] [in a new window]   Figure 2. Endothelial cell dysfunction: the impact of AGE. VCAM-1 indicates vascular cell adhesion molecule; ICAM, intercellular adhesion molecule; TF, tissue factor; AGE, advanced glycation end product; IL-6, interleukin-6; MCP-1, monocyte chemotactic protein-1; EC, endothelial cell; RBC, red blood cell; RAGE, receptor for AGE.

Two major microvascular complications of diabetes are retinopathy and nephropathy. In both settings, several lines of evidence suggest a deleterious effect of AGEs, either by direct action on endothelial cells or through a mechanism involving another cell type or the matrix components, present in the vicinity of the endothelium.¹⁹

	Retinopathy

Top Abstract Introduction Maillard Reaction Cellular and Extracellular AGE... Methylglyoxal Is Efficiently... Endothelial Cell Dysfunction Retinopathy Nephropathy Endothelial Cell Activation Endothelial Cell Growth,... Conclusion References

 
The first studies of ocular complications linked to glycation established the deleterious effects of AGE formation in pig crystallin in the pathogenesis of diabetic cataract.²⁰ One of the earliest changes observed in retinal microvessels is the selective loss of intramural pericytes, a process that may be linked to the effects of AGEs. AGEs may induce apoptosis and trigger oxidative stress of bovine pericytes.^21–23 In reaction to hypoxemia-induced microvascular damage, the retinal epithelial and endothelial cells increase production of vascular endothelial growth factor and promote neoangiogenesis, a process prevented by antibodies to RAGE.²⁴ Pyridoxamine, an inhibitor of AGE formation and lipoxidation end products, protects against diabetes-induced retinal vascular lesions.²⁵ The thiamine monophosphate derivative, benfotiamine, inhibits hyperglycemia-dependent pathways and NF-B activation, and prevents experimental diabetic retinopathy.²⁶ Beraprost sodium, a prostaglandin I2 analog, has been reported to protect retinal pericytes from AGE-induced cytotoxicity through its anti-oxidative properties and was previously shown to decrease vascular hyperpermeability in diabetic rats.^27–28

	Nephropathy

Top Abstract Introduction Maillard Reaction Cellular and Extracellular AGE... Methylglyoxal Is Efficiently... Endothelial Cell Dysfunction Retinopathy Nephropathy Endothelial Cell Activation Endothelial Cell Growth,... Conclusion References

 
Glomerulosclerosis observed in diabetic animals is associated with AGE deposition in mesangium and hyalinized and/or sclerotic lesions.²⁹ Levels of N-carboxymethyl-lysine adducts are increased in soluble proteins and insoluble collagen in patients with diabetes and renal impairment.^30,31 Overexpression of RAGE accelerates glomerulosclerosis development in mice.³² Pharmacological blockade of RAGE in db/db mice, or genetic deletion of RAGE in mice with streptozotocin-induced hyperglycemia, results in decreased albuminuria and mesangial expansion/glomerulosclerosis.³³

In renal failure, peritoneal dialysis treatment causes chemical peritonitis because of the limited biocompatibility of peritoneal dialysis fluids that contain high glucose concentrations (up to 45 g/L)³⁴ and, thus, glucose-derived products that are precursors of AGEs. Because RAGE is expressed on endothelial and mesothelial cells, the receptor may bind AGEs present in patients or formed during peritoneal dialysis. The binding of AGEs to RAGE produces a local inflammatory reaction, likely as a consequence of vascular cell adhesion molecule-1 overexpression, leukocyte adhesion, and cytokine release.³⁵

	Endothelial Cell Activation

Top Abstract Introduction Maillard Reaction Cellular and Extracellular AGE... Methylglyoxal Is Efficiently... Endothelial Cell Dysfunction Retinopathy Nephropathy Endothelial Cell Activation Endothelial Cell Growth,... Conclusion References

 
A key consequence of ligand engagement of RAGE is activation of multiple signaling pathways, including p21ras, erk 1/2 (p44/p42) MAP kinases, p38 and SAPK/JNK MAP kinases, rho GTPases, phosphoinositol-3 kinase and the JAK/STAT pathway, and downstream effectors such as NF-B and CREB.^36–37

Engagement of RAGE by AGE triggers the generation of reactive oxygen species. The incubation of human endothelial cells with specific AGE (carboxymethyl lysine-modified adducts) prompted intracellular generation of hydrogen peroxide, a process suppressed by diphenyliodonium but not by inhibitors of nitric oxide. Consistent with an important role for NADPH oxidase in AGE–RAGE–triggered events, macrophages derived from wild-type mice expressed enhanced levels of tissue factor on stimulation with AGE. In contrast, macrophages derived from mice deficient in gp91 phox failed to display enhanced tissue factor on incubation with AGEs (Figure 3). ³⁸

View larger version (16K): [in this window] [in a new window]   Figure 3. Reactive oxygen species formation. NADPH oxidase inhibitors: diphenyliodonium chloride (DPI) 4'hydroxy-3'-methoxy acetophenone (HMAP). Inhibitor of NO formation: NG monomethyl L arginine (LNMMA). SOD: superoxide dismutase.

Forearm resistance vessel responses to endothelium-dependent and independent agonists are abnormal in individuals with type I diabetes. The individuals with the highest HbA1c levels showed the most marked impairment in the response to acetylcholine.³⁹ These results are consistent with either reduced NO bioavailability or vascular smooth muscle cell responsiveness to NO.

Increased vascular permeability is characteristic of early diabetic vasculopathy. Postconfluent cultured endothelial cells incubated with red blood cells harvested from diabetic patients revealed increased diffusional transit (permeability of macromolecular tracers ¹²⁵I albumin and ³H inulin) compared with endothelial cells incubated with red blood cells from nondiabetic subjects. The diminution of endothelial cell barrier function was completely inhibited by anti-RAGE antibodies. Furthermore, in diabetic rats infused with soluble RAGE (60 µg/mL), hyperpermeability was blocked in intestine and skin and suppressed by 90% in the kidney.^40–41 Inhibition of AGEs and diabetic hyperpermeability by antioxidants both in vitro and in vivo suggested a central role of AGE–RAGE–induced oxidant stress in the development of hyperpermeability.^40–42 These studies strongly suggested that reactive oxygen species formation is a likely means by which oxidative stress can reversibly increase vascular permeability by rapid changes in endothelial cell shape via calcium-mediated pathways.^43–44 Reactive oxygen species can also increase permeability by quenching NO. Elevated serum levels of AGEs are correlated with the presence of microvascular complications (retinopathy, nephropathy); both of these conditions are associated with increased vascular permeability.⁴⁵

	Endothelial Cell Growth, Angiogenesis, and Accelerated Aging: The Impact of Glycation

Top Abstract Introduction Maillard Reaction Cellular and Extracellular AGE... Methylglyoxal Is Efficiently... Endothelial Cell Dysfunction Retinopathy Nephropathy Endothelial Cell Activation Endothelial Cell Growth,... Conclusion References

 
Angiogenesis and microvascular function are impaired in animal models of diabetes and collateral vessel development is inhibited in diabetic patients. Several factors have been proposed to contribute to abnormal neoangiogenesis in diabetes. For example, glycation of fibroblast growth factor 2 (FGF2) lowered its chemotactic effect toward endothelial cells, and when injected in normoglycemic mice, glycated FGF2 displayed a weaker angiogenic effect compared with nonglycated FGF2.⁴⁶ Glycation of bFGF with the intracellular sugars, fructose and glucose-6-phosphate, reduced its high-affinity heparin-binding capacity and its mitogenic activity.⁴⁷ These results suggested that reduced angiogenesis observed in diabetes may be a consequence of growth factor glycation. Direct inhibition of endothelial cell growth can be induced by high concentrations of ribose, which results in the generation of protein cross-links and eventually apoptosis.⁴⁸

Endothelial cells cultured on matrices containing glycated collagen display a defect in branching angiogenesis, in part by the early induction of PAI-1, which is accompanied by a time-dependent reduction in cell proliferation.⁴⁹ Glycated collagen induces premature endothelial cell senescence as indicated by the appearance of senescence-associated ß-galactosidase, increased cell size, and rate of apoptosis. This glycated collagen-induced senescence is associated with a decreased synthesis of NO. Premature senescence was also demonstrated in the aorta of Zucker diabetic rats, suggesting that premature senescence may contribute to diabetic vasculopathy.⁵⁰

RAGE overexpression is associated with an enhanced inflammation and expression of cyclooxygenase-2 and PGE synthase-1 in human diabetic atherosclerotic plaques. AGE formation has been shown to reduce proteolysis of glycated proteins and therefore may affect angiogenic pathways.^51–52 In diabetic and normal mice, hind limb ischemia was induced by right femoral artery ligature. After 28 days, the ischemic/nonischemic leg angiographic ratio was decreased by 1.4-fold in diabetic animals when compared with control animals. When diabetic mice were treated with aminoguanidine, the angiographic score was similar to the level observed in control animals. AGE blood levels were increased in the diabetic group 12.3-fold compared with control mice, and aminoguanidine treatment decreased the AGE plasma level by 4.2-fold compared with untreated diabetic mice. Blockade of AGE formation normalized impaired ischemia-induced angiogenesis in diabetic mice. This effect is probably mediated by restoration of matrix degradation processes that are disturbed as a result of AGE accumulation.⁵²

Endothelial cells from different locations in the vascular tree respond differently to various stimuli and receptors are expressed to different degrees. Whether other receptors in addition to RAGE transduce the effects of AGEs in the vasculature remains to be fully determined. AGE–R3 galectin 3 is proposed as a scavenger receptor, because mice genetically devoid of AGE–R3 develop a rapid glomerulosclerosis compared with wild-type animals.⁹

CD34⁺ cells from nondiabetic human subjects displayed no benefit when infused into nondiabetic mice with hind limb ischemia; these same cells exerted a profound increase in restoration of blood flow when infused into diabetic mice.⁵³ Consistent with the premise that progenitor cells may be impaired in diabetes, cultured CD34⁺ blood cells retrieved from type 1 diabetic subjects produced fewer endothelial cells per milliliter of blood compared with cells retrieved from the same amount of blood retrieved from nondiabetic subjects.⁵³

	Conclusion

Top Abstract Introduction Maillard Reaction Cellular and Extracellular AGE... Methylglyoxal Is Efficiently... Endothelial Cell Dysfunction Retinopathy Nephropathy Endothelial Cell Activation Endothelial Cell Growth,... Conclusion References

 
Blockade of AGE and cross-link formation may be achieved by administration of compounds such as aminoguanidine, pyridoxamine or OPB9195 [±(–2 iso-propylidenehydrodrazono-4-oxo-thiazodilin-5-ylacetanidide].⁵⁴ A second method for inhibiting AGE effects is to target RAGE.⁴¹ Agents mimicking the protective effects of soluble RAGE are under development.³⁸ Cross-link breakers that contain thiazolium structure can break a carbonyl compounds. ALT-711 (4,5-dimethyl-3-phenacylthiozolium chloride) has been the most widely studied agent in this class and has been shown to enhance collagen solubility and to reduce expression of RAGE and AGE–R3 mRNA in diabetic rats. This molecule is now in advanced phase II clinical trials to clarify its potential therapeutic use.⁵⁵

The negative impact of hyperglycemia on endothelial function and pathological changes is supported by a large series of published studies. High-glucose flux through glucose transporters on endothelial cells overwhelms the mitochondrial electron transport system. Excess mitochondrial substrate flux results in the generation of reactive oxygen species. In conclusion, although reduction of AGEs is possibly an achievable goal in the clinic, such an outcome may not be compatible with life. It is highly likely that to age gracefully, a delicate balance between tolerable versus deleterious levels of AGEs in the body must be struck.

	Acknowledgments

 
We are indebted to Frederique Vileyn for her excellent technical assistance. We are funded by the Université Paris 7, Institut National de la Transfusion Sanguine, Paris, France.

	Footnotes

 
Original received February 20, 2004; revision received May 10, 2004; accepted May 28, 2004.

	References

Top Abstract Introduction Maillard Reaction Cellular and Extracellular AGE... Methylglyoxal Is Efficiently... Endothelial Cell Dysfunction Retinopathy Nephropathy Endothelial Cell Activation Endothelial Cell Growth,... Conclusion References

 
1. Maillard. LC. Formation d’humus et de combustibles minéraux sans intervention de l’oxygène atmosphérique, des micro-organismes, des hautes températures ou fortes pressions. C R Acad Sci (Paris). 1912; 154: 1554–1556.

2. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997; 99: 457–468.[Medline] [Order article via Infotrieve]

3. Ahmed N, Thornalley PJ. Quantitative screening of protein biomarkers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring. Biochem Soc Trans. 2003; 31: 1417–1422.[Medline] [Order article via Infotrieve]

4. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res. 2001; 56: 1–21.[Abstract]

5. Cerami A, Ulrich P. Pharmaceutical intervention of advanced glycation endproducts. Novartis Found Symp. 2001; 235: 202–212.[Medline] [Order article via Infotrieve]

6. Brownlee M. Advanced glycation end products in diabetic complications. Curr Opin Endocrinol Diabetes. 1996; 3: 291–297.

7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414: 813–820.[CrossRef][Medline] [Order article via Infotrieve]

8. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 1994; 14: 1521–1528.[Abstract/Free Full Text]

9. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab. 2001; 27: 535–542.[Medline] [Order article via Infotrieve]

10. Brownlee M. Negative consequences of glycation. Metabolism. 2000; 49: 9–13.[Medline] [Order article via Infotrieve]

11. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, Brownlee M. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest. 1998; 101: 1142–1147.[Medline] [Order article via Infotrieve]

12. Thornalley PJ. Glyoxalase I–structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans. 2003; 31: 1343–1348.[Medline] [Order article via Infotrieve]

13. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988; 318: 1315–1321.[Medline] [Order article via Infotrieve]

14. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation. 2003; 108: 1917–1923.[Free Full Text]

15. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med. 1995; 1: 447–456.[Medline] [Order article via Infotrieve]

16. Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986; 163: 1363–1375.[Abstract/Free Full Text]

17. Montgomery KF, Osborn L, Hession C, Tizard R, Goff D, Vassallo C, Tarr PI, Bomsztyk K, Lobb R, Harlan JM, et al. Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Proc Natl Acad Sci U S A. 1991; 88: 6523–6527.[Abstract/Free Full Text]

18. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984; 160: 618–623.[Abstract/Free Full Text]

19. Chappey O, Dosquet C, Wautier MP, Wautier JL. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest. 1997; 27: 97–108.[CrossRef][Medline] [Order article via Infotrieve]

20. Vidal P, Cabezas-Cerrato J. The stable products of the non-enzymatic glycation of pig crystallins: new findings related to the pathogenesis of diabetic cataracts. Diabetes Res. 1988; 8: 183–187.[Medline] [Order article via Infotrieve]

21. Denis U, Lecomte M, Paget C, Ruggiero D, Wiernsperger N, Lagarde M. Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture: involvement of diacylglycerol/ceramide production and oxidative stress induction. Free Radic Biol Med. 2002; 33: 236–247.[CrossRef][Medline] [Order article via Infotrieve]

22. Moore TC, Moore JE, Kaji Y, Frizzell N, Usui T, Poulaki V, Campbell IL, Stitt AW, Gardiner TA, Archer DB, Adamis AP. The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci. 2003; 44: 4457–4464.[Abstract/Free Full Text]

23. Nakamura N, Hasegawa G, Obayashi H, Yamazaki M, Ogata M, Nakano K, Yoshikawa T, Watanabe A, Kinoshita S, Fujinami A, Ohta M, Imamura Y, Ikeda T. Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2003; 61: 93–101.[CrossRef][Medline] [Order article via Infotrieve]

24. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003; 370: 1097–1109.[CrossRef][Medline] [Order article via Infotrieve]

25. Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR: The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002; 51: 2826–2832.[Abstract/Free Full Text]

26. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003; 9: 294–299.[CrossRef][Medline] [Order article via Infotrieve]

27. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Takeuchi M, Makita Z. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes. Mol Med. 2002; 8: 546–550.[Medline] [Order article via Infotrieve]

28. Zoukourian C, Wautier MP, Chappey O, Dosquet C, Rohban T, Schmidt AM, Stern D, Wautier JL. Endothelial cell dysfunction secondary to the adhesion of diabetic erythrocytes. Modulation by iloprost. Int Angiol. 1996; 15: 195–200.[Medline] [Order article via Infotrieve]

29. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991; 325: 836–842.[Abstract]

30. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley PJ. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans. 2003; 31: 1423–1425.[Medline] [Order article via Infotrieve]

31. Weiss MF, Erhard P, Kader-Attia FA, Wu YC, Deoreo PB, Araki A, Glomb MA, Monnier VM. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int. 2000; 57: 2571–2585.[CrossRef][Medline] [Order article via Infotrieve]

32. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001; 108: 261–268.[CrossRef][Medline] [Order article via Infotrieve]

33. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D’Agati VD, Schmidt AM. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003; 162: 1123–1137.[Abstract/Free Full Text]

34. Booth AA, Khalifah RG, Todd P, Hudson BG. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem. 1997; 272: 5430–5437.[Abstract/Free Full Text]

35. Boulanger E, Wautier MP, Wautier JL, Boval B, Panis Y, Wernert N, Danze PM, Dequiedt P. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int. 2002; 61: 148–156.[CrossRef][Medline] [Order article via Infotrieve]

36. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002; 105: 816–822.[Abstract/Free Full Text]

37. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res. 2003; 93: 1159–1169.[Abstract/Free Full Text]

38. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001; 280: E685–E694.[Abstract/Free Full Text]

39. Chan NN, Vallance P, Colhoun HM. Endothelium-dependent and independent vascular dysfunction in type 1 diabetes. Role of conventional risk factors, sex and glycemic control. Arterioscler Thromb Vasc Biol. 2003; 23: 1048–1054.[Abstract/Free Full Text]

40. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest. 1996; 97: 238–243.[Medline] [Order article via Infotrieve]

41. Renard C, Chappey O, Wautier MP, Nagashima M, Morser J, Scherrmann JM, Wautier JL. The human and rat recombinant receptors for advanced glycation end products have a high degree of homology but different pharmacokinetic properties in rats. J Pharmacol Exp Ther. 1999; 290: 1458–1466.[Abstract/Free Full Text]

42. Bonnardel-Phu E, Wautier JL, Schmidt AM, Avila C, Vicaut E. Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo. Diabetes. 1999; 48: 2052–2058.[Abstract]

43. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996; 19: 257–267.[Abstract]

44. Siflinger-Birnboim A, Lum H, Del Vecchio PJ, Malik AB. Involvement of Ca2+ in the H2O2-induced increase in endothelial permeability. Am J Physiol. 1996; 270: L973–L978.[Medline] [Order article via Infotrieve]

45. Wautier MP, Massin P, Guillausseau PJ, Huijberts M, Levy B, Boulanger E, Laloi-Michelin M, Wautier JL. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab. 2003; 29: 44–52.[Medline] [Order article via Infotrieve]

46. Facchiano F, Lentini A, Fogliano V, Mancarella S, Rossi C, Facchiano A, Capogrossi MC. Sugar-induced modification of fibroblast growth factor 2 reduces its angiogenic activity in vivo. Am J Pathol. 2002; 161: 531–541.[Abstract/Free Full Text]

47. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest. 1994; 94: 110–117.[Medline] [Order article via Infotrieve]

48. Talasz H, Wasserer S, Puschendorf B. Nonenzymatic glycation of histones in vitro and in vivo. J Cell Biochem. 2002; 85: 24–34.[CrossRef][Medline] [Order article via Infotrieve]

49. Chen J. Brodsky S, Li H, Hampel DJ, Miyata T, Weinstein T, Gafter U, Norman JT, Fine LG, Goligorsky MS. Delayed branching of endothelial capillary like cords in glycated collagen I is mediated by early induction of PAI-1. Am J Physiol Renal Physiol. 2001; 281: F71–F80.[Abstract/Free Full Text]

50. Chen J, Brodsky SV, Goligorsky DM, Hampel DJ, Li H, Gross SS, Goligorsky MS. Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ Res. 2002; 90: 1290–1298.[Abstract/Free Full Text]

51. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation. 2003; 108: 1070–1077.[Abstract/Free Full Text]

52. Tamarat R, Silvestre JS, Huijberts M, Benessiano J, Ebrahimian TG, Duriez M, Wautier MP, Wautier JL, Levy BI. Blockade of advanced glycation end-products formation restores ischemia induced angiogenesis in diabetic mice. Proc Natl Acad Sci U S A. 2003; 100: 8555–8560.[Abstract/Free Full Text]

53. Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest. 2000; 106: 571–578.[Medline] [Order article via Infotrieve]

54. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001; 104: 1464–1470.[Abstract/Free Full Text]

55. Kass DA. Getting better without AGE: new insights into the diabetic heart. Circ Res. 2003; 92: 704–706.[Free Full Text]

This article has been cited by other articles:

				D Joshi, A Shiwalkar, M R Cross, S K Sharma, A Vachhani, and C Dutt Continuous, non-invasive measurement of the haemodynamic response to submaximal exercise in patients with diabetes mellitus: evidence of impaired cardiac reserve and peripheral vascular response Heart, January 1, 2010; 96(1): 36 - 41. [Abstract] [Full Text] [PDF]

				D. S. Wilkes Primary Graft Dysfunction: It's All the RAGE Am. J. Respir. Crit. Care Med., November 15, 2009; 180(10): 915 - 916. [Full Text] [PDF]

				J. D. Christie, C. V. Shah, S. M. Kawut, N. Mangalmurti, D. J. Lederer, J. R. Sonett, V. N. Ahya, S. M. Palmer, K. Wille, V. Lama, et al. Plasma Levels of Receptor for Advanced Glycation End Products, Blood Transfusion, and Risk of Primary Graft Dysfunction Am. J. Respir. Crit. Care Med., November 15, 2009; 180(10): 1010 - 1015. [Abstract] [Full Text] [PDF]

				O. KUCUKHUSEYIN, H. Y. AYDOGAN, C. S. ISBIR, and T. ISBIR Associations of -374T/A Polymorphism of Receptor for Advanced Glycation End Products (RAGE) Gene in Turkish Diabetic and Non-diabetic Patients with Coronary Artery Disease In Vivo, November 1, 2009; 23(6): 949 - 954. [Abstract] [Full Text] [PDF]

				S. P. Baba, O. A. Barski, Y. Ahmed, T. E. O'Toole, D. J. Conklin, A. Bhatnagar, and S. Srivastava Reductive Metabolism of AGE Precursors: A Metabolic Route for Preventing AGE Accumulation in Cardiovascular Tissue Diabetes, November 1, 2009; 58(11): 2486 - 2497. [Abstract] [Full Text] [PDF]

				H. Maillard-Lefebvre, E. Boulanger, M. Daroux, C. Gaxatte, B. I. Hudson, and M. Lambert Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases Rheumatology, October 1, 2009; 48(10): 1190 - 1196. [Abstract] [Full Text] [PDF]

				C. A. Davies, A. L. Herrick, L. Cordingley, A. J. Freemont, and M. Jeziorska Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis Rheumatology, August 1, 2009; 48(8): 876 - 882. [Abstract] [Full Text] [PDF]

				S. Ignace, D. Fouque, W. Arkouche, J.-P. Steghens, and F. Guebre-Egziabher Preserved residual renal function is associated with lower oxidative stress in peritoneal dialysis patients Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1685 - 1689. [Abstract] [Full Text] [PDF]

				R. Siekmeier, T. Grammer, and W. Marz Roles of Oxidants, Nitric Oxide, and Asymmetric Dimethylarginine in Endothelial Function Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2008; 13(4): 279 - 297. [Abstract] [PDF]

				N. Katakami, M. Matsuhisa, H. Kaneto, T.-A. Matsuoka, K. Sakamoto, T. Yasuda, and Y. Yamasaki Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients Diabetes and Vascular Disease Research, September 1, 2008; 5(3): 190 - 197. [Abstract] [PDF]

				A. Soro-Paavonen, A. M.D. Watson, J. Li, K. Paavonen, A. Koitka, A. C. Calkin, D. Barit, M. T. Coughlan, B. G. Drew, G. I. Lancaster, et al. Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes Diabetes, September 1, 2008; 57(9): 2461 - 2469. [Abstract] [Full Text] [PDF]

				K. Omori, T. Ohira, Y. Uchida, S. Ayilavarapu, E. L. Batista Jr., M. Yagi, T. Iwata, H. Liu, H. Hasturk, A. Kantarci, et al. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase J. Leukoc. Biol., July 1, 2008; 84(1): 292 - 301. [Abstract] [Full Text] [PDF]

				Y. Talmor, E. Golan, S. Benchetrit, J. Bernheim, O. Klein, J. Green, and G. Rashid Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1059 - F1064. [Abstract] [Full Text] [PDF]

				M. Boodhwani, N. R. Sodha, S. Mieno, B. Ramlawi, S.-H. Xu, J. Feng, R. T. Clements, M. Ruel, and F. W. Sellke Insulin treatment enhances the myocardial angiogenic response in diabetes. J. Thorac. Cardiovasc. Surg., December 1, 2007; 134(6): 1453 - 1460. [Abstract] [Full Text] [PDF]

				G. Ceolotto, A. Gallo, I. Papparella, L. Franco, E. Murphy, E. Iori, E. Pagnin, G. P. Fadini, M. Albiero, A. Semplicini, et al. Rosiglitazone Reduces Glucose-Induced Oxidative Stress Mediated by NAD(P)H Oxidase via AMPK-Dependent Mechanism Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2627 - 2633. [Abstract] [Full Text] [PDF]

				D. A. Rao, K. J. Tracey, and J. S. Pober IL-1{alpha} and IL-1beta Are Endogenous Mediators Linking Cell Injury to the Adaptive Alloimmune Response J. Immunol., November 15, 2007; 179(10): 6536 - 6546. [Abstract] [Full Text] [PDF]

				S. Gundewar, J. W. Calvert, J. W. Elrod, and D. J. Lefer Cytoprotective effects of N,N,N-trimethylsphingosine during ischemia- reperfusion injury are lost in the setting of obesity and diabetes Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2462 - H2471. [Abstract] [Full Text] [PDF]

				K. de Leeuw, R. Graaff, R. de Vries, R. P. Dullaart, A. J. Smit, C. G. Kallenberg, and M. Bijl Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus Rheumatology, October 1, 2007; 46(10): 1551 - 1556. [Abstract] [Full Text] [PDF]

				D. Navaratna, P. G. McGuire, G. Menicucci, and A. Das Proteolytic Degradation of VE-Cadherin Alters the Blood-Retinal Barrier in Diabetes Diabetes, September 1, 2007; 56(9): 2380 - 2387. [Abstract] [Full Text] [PDF]

				C. Mallidis, I. Agbaje, D. Rogers, J. Glenn, S. McCullough, A. B. Atkinson, K. Steger, A. Stitt, and N. McClure Distribution of the receptor for advanced glycation end products in the human male reproductive tract: prevalence in men with diabetes mellitus Hum. Reprod., August 1, 2007; 22(8): 2169 - 2177. [Abstract] [Full Text] [PDF]

				D. A Stakos, D. P Schuster, E. A Sparks, S. B. Meis, C. F Wooley, K. Osei, and H. Boudoulas Association between glycosylated hemoglobin, left ventricular mass and aortic function in nondiabetic individuals with insulin resistance Eur. J. Endocrinol., July 1, 2007; 157(1): 63 - 68. [Abstract] [Full Text] [PDF]

				J. Han, A. E. Woytowich, A. K. Mandal, and L. M. Hiebert Heparanase Upregulation in High Glucose-Treated Endothelial Cells Is Prevented by Insulin and Heparin Exp Biol Med, July 1, 2007; 232(7): 927 - 934. [Abstract] [Full Text] [PDF]

				F. Galli Protein damage and inflammation in uraemia and dialysis patients Nephrol. Dial. Transplant., July 1, 2007; 22(suppl_5): v20 - v36. [Abstract] [Full Text] [PDF]

				G. B. Atkins and M. K. Jain Role of Kruppel-Like Transcription Factors in Endothelial Biology Circ. Res., June 22, 2007; 100(12): 1686 - 1695. [Abstract] [Full Text] [PDF]

				G. Marsche, M. Semlitsch, A. Hammer, S. Frank, B. Weigle, N. Demling, K. Schmidt, W. Windischhofer, G. Waeg, W. Sattler, et al. Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway FASEB J, April 1, 2007; 21(4): 1145 - 1152. [Abstract] [Full Text] [PDF]

				F. Facchiano, D. D'Arcangelo, K. Russo, V. Fogliano, C. Mennella, R. Ragone, G. Zambruno, V. Carbone, D. Ribatti, C. Peschle, et al. Glycated Fibroblast Growth Factor-2 Is Quickly Produced in Vitro upon Low-Millimolar Glucose Treatment and Detected in Vivo in Diabetic Mice Mol. Endocrinol., November 1, 2006; 20(11): 2806 - 2818. [Abstract] [Full Text] [PDF]

				H. J. Zhao, S. Wang, H. Cheng, M.-z. Zhang, T. Takahashi, A. B. Fogo, M. D. Breyer, and R. C. Harris Endothelial Nitric Oxide Synthase Deficiency Produces Accelerated Nephropathy in Diabetic Mice J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2664 - 2669. [Abstract] [Full Text] [PDF]

				A. G. Huebschmann, J. G. Regensteiner, H. Vlassara, and J. E.B. Reusch Diabetes and Advanced Glycoxidation End Products. Diabetes Care, June 1, 2006; 29(6): 1420 - 1432. [Full Text] [PDF]

				C. Demiot, M. Tartas, B. Fromy, P. Abraham, J. L. Saumet, and D. Sigaudo-Roussel Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy. Diabetes, May 1, 2006; 55(5): 1478 - 1483. [Abstract] [Full Text] [PDF]

				F. Stam, C. G. Schalkwijk, C. van Guldener, P. M. ter Wee, and C. D. A. Stehouwer Advanced glycation end-product peptides are associated with impaired renal function, but not with biochemical markers of endothelial dysfunction and inflammation, in non-diabetic individuals Nephrol. Dial. Transplant., March 1, 2006; 21(3): 677 - 682. [Abstract] [Full Text] [PDF]

				N. Katakami, M. Matsuhisa, H. Kaneto, and Y. Yamasaki Endogenous secretory receptor for advanced glycation end product levels are inversely associated with HbA1c in type 2 diabetic patients. Diabetes Care, February 1, 2006; 29(2): 469 - 469. [Full Text] [PDF]

				N. Katakami, M. Matsuhisa, H. Kaneto, T.-a. Matsuoka, K. Sakamoto, Y. Nakatani, K. Ohtoshi, R. Hayaishi-Okano, K. Kosugi, M. Hori, et al. Decreased Endogenous Secretory Advanced Glycation End Product Receptor in Type 1 Diabetic Patients: Its possible association with diabetic vascular complications Diabetes Care, November 1, 2005; 28(11): 2716 - 2721. [Abstract] [Full Text] [PDF]

				J. H. Southerland, G. W. Taylor, and S. Offenbacher Diabetes and Periodontal Infection: Making the Connection Clin. Diabetes, October 1, 2005; 23(4): 171 - 178. [Abstract] [Full Text] [PDF]

				J. M. Bohlender, S. Franke, G. Stein, and G. Wolf Advanced glycation end products and the kidney Am J Physiol Renal Physiol, October 1, 2005; 289(4): F645 - F659. [Abstract] [Full Text] [PDF]

				S. S. Najjar, A. Scuteri, and E. G. Lakatta Arterial Aging: Is It an Immutable Cardiovascular Risk Factor? Hypertension, September 1, 2005; 46(3): 454 - 462. [Abstract] [Full Text] [PDF]

				R. Ramasamy, S. J. Vannucci, S. S. D. Yan, K. Herold, S. F. Yan, and A. M. Schmidt Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation Glycobiology, July 1, 2005; 15(7): 16R - 28R. [Abstract] [Full Text] [PDF]

				J. M. Cacicedo, S. Benjachareowong, E. Chou, N. B. Ruderman, and Y. Ido Palmitate-Induced Apoptosis in Cultured Bovine Retinal Pericytes: Roles of NAD(P)H Oxidase, Oxidant Stress, and Ceramide Diabetes, June 1, 2005; 54(6): 1838 - 1845. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wautier, J.-L. Articles by Schmidt, A. M. Search for Related Content PubMed PubMed Citation Articles by Wautier, J.-L. Articles by Schmidt, A. M. Related Collections Endothelium/vascular type/nitric oxide Mechanism of atherosclerosis/growth factors